Cargando…

The Potential Prebiotic Berberine Combined With Methimazole Improved the Therapeutic Effect of Graves’ Disease Patients Through Regulating the Intestinal Microbiome

Graves’ disease, a typical metabolism disorder, causes diffuse goiter accompanied by ocular abnormalities and ocular dysfunction. Although methimazole (MI) is a commonly used drug for the treatment of GD, the efficacy of methimazole is only limited to the control of clinical indicators, and the side...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Zhe, Cen, Chaoping, Ou, Qianying, Pan, Yonggui, Zhang, Jiachao, Huo, Dongxue, Chen, Kaining
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785824/
https://www.ncbi.nlm.nih.gov/pubmed/35082799
http://dx.doi.org/10.3389/fimmu.2021.826067
_version_ 1784639029305671680
author Han, Zhe
Cen, Chaoping
Ou, Qianying
Pan, Yonggui
Zhang, Jiachao
Huo, Dongxue
Chen, Kaining
author_facet Han, Zhe
Cen, Chaoping
Ou, Qianying
Pan, Yonggui
Zhang, Jiachao
Huo, Dongxue
Chen, Kaining
author_sort Han, Zhe
collection PubMed
description Graves’ disease, a typical metabolism disorder, causes diffuse goiter accompanied by ocular abnormalities and ocular dysfunction. Although methimazole (MI) is a commonly used drug for the treatment of GD, the efficacy of methimazole is only limited to the control of clinical indicators, and the side effects of MI should be seriously considered. Here, we designed a 6-month clinical trial that divided the patients into two groups: a methimazole group (n=8) and a methimazole combined with potential prebiotic berberine group (n=10). The effects of both treatments on thyroid function and treatment outcomes in patients with GD were assessed by thyroid index measurements and gut microbiota metagenomic sequencing. The results showed that the addition of berberine restored the patients’ TSH and FT3 indices to normal levels, whereas MI alone restored only FT3. In addition, TRAb was closer to the healthy threshold at the end of treatment with the drug combination. MI alone failed to modulate the gut microbiota of the patients. However, the combination of berberine with methimazole significantly altered the microbiota structure of the patients, increasing the abundance of the beneficial bacteria Lactococcus lactis while decreasing the abundance of the pathogenic bacteria Enterobacter hormaechei and Chryseobacterium indologenes. Furthermore, further mechanistic exploration showed that the addition of berberine resulted in a significant upregulation of the synthesis of enterobactin, which may have increased iron functioning and thus restored thyroid function. In conclusion, methimazole combined with berberine has better efficacy in patients with GD, suggesting the potential benefit of berberine combined with methimazole in modulating the composition of intestinal microbes in the treatment of GD, providing new strong evidence for the effectiveness of combining Chinese and Western drugs from the perspective of modulating the intestinal microbiota.
format Online
Article
Text
id pubmed-8785824
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87858242022-01-25 The Potential Prebiotic Berberine Combined With Methimazole Improved the Therapeutic Effect of Graves’ Disease Patients Through Regulating the Intestinal Microbiome Han, Zhe Cen, Chaoping Ou, Qianying Pan, Yonggui Zhang, Jiachao Huo, Dongxue Chen, Kaining Front Immunol Immunology Graves’ disease, a typical metabolism disorder, causes diffuse goiter accompanied by ocular abnormalities and ocular dysfunction. Although methimazole (MI) is a commonly used drug for the treatment of GD, the efficacy of methimazole is only limited to the control of clinical indicators, and the side effects of MI should be seriously considered. Here, we designed a 6-month clinical trial that divided the patients into two groups: a methimazole group (n=8) and a methimazole combined with potential prebiotic berberine group (n=10). The effects of both treatments on thyroid function and treatment outcomes in patients with GD were assessed by thyroid index measurements and gut microbiota metagenomic sequencing. The results showed that the addition of berberine restored the patients’ TSH and FT3 indices to normal levels, whereas MI alone restored only FT3. In addition, TRAb was closer to the healthy threshold at the end of treatment with the drug combination. MI alone failed to modulate the gut microbiota of the patients. However, the combination of berberine with methimazole significantly altered the microbiota structure of the patients, increasing the abundance of the beneficial bacteria Lactococcus lactis while decreasing the abundance of the pathogenic bacteria Enterobacter hormaechei and Chryseobacterium indologenes. Furthermore, further mechanistic exploration showed that the addition of berberine resulted in a significant upregulation of the synthesis of enterobactin, which may have increased iron functioning and thus restored thyroid function. In conclusion, methimazole combined with berberine has better efficacy in patients with GD, suggesting the potential benefit of berberine combined with methimazole in modulating the composition of intestinal microbes in the treatment of GD, providing new strong evidence for the effectiveness of combining Chinese and Western drugs from the perspective of modulating the intestinal microbiota. Frontiers Media S.A. 2022-01-10 /pmc/articles/PMC8785824/ /pubmed/35082799 http://dx.doi.org/10.3389/fimmu.2021.826067 Text en Copyright © 2022 Han, Cen, Ou, Pan, Zhang, Huo and Chen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Han, Zhe
Cen, Chaoping
Ou, Qianying
Pan, Yonggui
Zhang, Jiachao
Huo, Dongxue
Chen, Kaining
The Potential Prebiotic Berberine Combined With Methimazole Improved the Therapeutic Effect of Graves’ Disease Patients Through Regulating the Intestinal Microbiome
title The Potential Prebiotic Berberine Combined With Methimazole Improved the Therapeutic Effect of Graves’ Disease Patients Through Regulating the Intestinal Microbiome
title_full The Potential Prebiotic Berberine Combined With Methimazole Improved the Therapeutic Effect of Graves’ Disease Patients Through Regulating the Intestinal Microbiome
title_fullStr The Potential Prebiotic Berberine Combined With Methimazole Improved the Therapeutic Effect of Graves’ Disease Patients Through Regulating the Intestinal Microbiome
title_full_unstemmed The Potential Prebiotic Berberine Combined With Methimazole Improved the Therapeutic Effect of Graves’ Disease Patients Through Regulating the Intestinal Microbiome
title_short The Potential Prebiotic Berberine Combined With Methimazole Improved the Therapeutic Effect of Graves’ Disease Patients Through Regulating the Intestinal Microbiome
title_sort potential prebiotic berberine combined with methimazole improved the therapeutic effect of graves’ disease patients through regulating the intestinal microbiome
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785824/
https://www.ncbi.nlm.nih.gov/pubmed/35082799
http://dx.doi.org/10.3389/fimmu.2021.826067
work_keys_str_mv AT hanzhe thepotentialprebioticberberinecombinedwithmethimazoleimprovedthetherapeuticeffectofgravesdiseasepatientsthroughregulatingtheintestinalmicrobiome
AT cenchaoping thepotentialprebioticberberinecombinedwithmethimazoleimprovedthetherapeuticeffectofgravesdiseasepatientsthroughregulatingtheintestinalmicrobiome
AT ouqianying thepotentialprebioticberberinecombinedwithmethimazoleimprovedthetherapeuticeffectofgravesdiseasepatientsthroughregulatingtheintestinalmicrobiome
AT panyonggui thepotentialprebioticberberinecombinedwithmethimazoleimprovedthetherapeuticeffectofgravesdiseasepatientsthroughregulatingtheintestinalmicrobiome
AT zhangjiachao thepotentialprebioticberberinecombinedwithmethimazoleimprovedthetherapeuticeffectofgravesdiseasepatientsthroughregulatingtheintestinalmicrobiome
AT huodongxue thepotentialprebioticberberinecombinedwithmethimazoleimprovedthetherapeuticeffectofgravesdiseasepatientsthroughregulatingtheintestinalmicrobiome
AT chenkaining thepotentialprebioticberberinecombinedwithmethimazoleimprovedthetherapeuticeffectofgravesdiseasepatientsthroughregulatingtheintestinalmicrobiome
AT hanzhe potentialprebioticberberinecombinedwithmethimazoleimprovedthetherapeuticeffectofgravesdiseasepatientsthroughregulatingtheintestinalmicrobiome
AT cenchaoping potentialprebioticberberinecombinedwithmethimazoleimprovedthetherapeuticeffectofgravesdiseasepatientsthroughregulatingtheintestinalmicrobiome
AT ouqianying potentialprebioticberberinecombinedwithmethimazoleimprovedthetherapeuticeffectofgravesdiseasepatientsthroughregulatingtheintestinalmicrobiome
AT panyonggui potentialprebioticberberinecombinedwithmethimazoleimprovedthetherapeuticeffectofgravesdiseasepatientsthroughregulatingtheintestinalmicrobiome
AT zhangjiachao potentialprebioticberberinecombinedwithmethimazoleimprovedthetherapeuticeffectofgravesdiseasepatientsthroughregulatingtheintestinalmicrobiome
AT huodongxue potentialprebioticberberinecombinedwithmethimazoleimprovedthetherapeuticeffectofgravesdiseasepatientsthroughregulatingtheintestinalmicrobiome
AT chenkaining potentialprebioticberberinecombinedwithmethimazoleimprovedthetherapeuticeffectofgravesdiseasepatientsthroughregulatingtheintestinalmicrobiome